MD Anderson’s patient-centric approach to research is advancing the understanding of malignant and non-malignant blood disorders and extending patients’ lives.
At the ASH Annual Meeting and Exposition, our experts showcased their practice-changing work with colleagues from across the globe for large-scale discussion.
Below is a snapshot of the work our experts presented at the 2019 meeting, as well as more about our pioneering hematology research. Bookmark this page for updates about next year’s meeting and beyond.
CAR T cell therapy has changed the way B-cell lymphoma is treated, but there’s work to be done to make this immunotherapy more effective with fewer side effects. Paolo Strati, M.D., discusses research that’s underway.
There is significant diversity within each patient’s cancer cells,
and those distinct groups of cells can respond differently to
treatments. MD Anderson researchers are working to better understand
this diversity to deliver more tailored treatment options.
Chemotherapy has long been the standard treatment for B-cell lymphoma, but it doesn’t work for everyone. Molecular testing and targeted therapies are making treatments more effective while helping maintain patients’ quality of life.
MD Anderson News
Conferences and Educational Events
View a list of professional, CME-accredited conferences and educational events.
Moon Shots Program
Our intentions are noble – put blood cancers at the forefront of our investigation to make their cure a future reality. Our process is groundbreaking – use in-house, industry-quality platforms to ensure that our breakthrough discoveries aren’t left sitting in research labs.
By combining Innovation, Collaboration and Scale, the Moon Shots Program® is revolutionizing the conventional medical research approach to rapidly adapt pre-clinical findings into treatment options for challenging blood cancers.